Cargando…
L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients
Background: Non-small cell lung cancer (NSCLC) is a common and highly lethal disease. As advanced treatment modalities are being developed, improved prognostication methods are sought. L3 skeletal muscle index (L3SMI) and alanine aminotransferase (ALT) levels are accepted surrogate markers of sarcop...
Autores principales: | Portal, D, Hofstetter, L, Eshed, I, Dan-Lantsman, C, Sella, T, Urban, D, Onn, A, Bar, J, Segal, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497853/ https://www.ncbi.nlm.nih.gov/pubmed/31114324 http://dx.doi.org/10.2147/CMAR.S195869 |
Ejemplares similares
-
Sarcopenia as Manifested by L3SMI Is Associated with Increased Long-Term Mortality amongst Internal Medicine Patients—A Prospective Cohort Study
por: Portal, Doron, et al.
Publicado: (2022) -
Sarcopenia defined with L3-SMI is an independent predictor of survival in male patients with ARLD in mainland China
por: Zhang, Yu, et al.
Publicado: (2023) -
Untailored vs. Gender- and Body-Mass-Index-Tailored Skeletal Muscle Mass Index (SMI) to Assess Sarcopenia in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Morelli, Cristina, et al.
Publicado: (2023) -
The DATE SMI run control, pt.3
por: CERN. Geneva
Publicado: (2001) -
SMI-2
Publicado: (No d)